Skip to content

Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population

A Multi-center Randomized Control Study of Bronchoscopy in Early Lung Cancer Screening of High Risk Population

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02277366
Enrollment
400
Registered
2014-10-29
Start date
2015-05-31
Completion date
2017-11-30
Last updated
2015-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

Lung Neoplasms, Bronchoscopy, Early Detection of Cancer

Brief summary

The purpose of this study is to determine the diagnostic yield of early lung cancer in high risk population, who smokes or has other risk factors, by different bronchoscopy,. Furthermore, another purpose is to determine whether the different bronchoscopy are significant different in diagnosing early lung cancer.

Interventions

PROCEDUREFluorescence Bronchoscopy/Narrow Band Bronchoscopy

Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.

Sponsors

Changhai Hospital
CollaboratorOTHER
The First Affiliated Hospital of Guangzhou Medical University
CollaboratorOTHER
Xinqiao Hospital of Chongqing
CollaboratorOTHER
China Meitan General Hospital
CollaboratorOTHER
Micro-Tech (Nanjing) Co., Ltd.
CollaboratorINDUSTRY
Tang-Du Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patient is over 40 years in age and is a heavy cigarette smoker.(smoking index is over 400) * Patient has been coughing irritably for 2-3 weeks with a failed treatment and without obvious causes. * The nature of cough changes in a patient who has chronic respiratory disease. * Patient has blood-stained sputum persistently or repeatedly without obvious causes. Patient will be included if accorded with any item of above.

Exclusion criteria

* Patient has dysrhythmia or cardiovascular disease that poses a risk during exercise. * Patient has uncontrollable hypertension (SBP \> 180mmHg). * Patient has severe organ dysfunction (shock, severe hepatic and renal dysfunction, massive hemorrhage of upper gastrointestine, diffuse intravascular coagulation(DIC) and massive hemoptysis,etc). * Patient has blood coagulation disorders (PT\>2 times the upper limit of normal(ULN) or Platelet(PLT)\<50000/ul). * Patient has severe dyspnea. * Patient is allergic to local anesthetic. * Patient is unable to provide informed consent. * Patient is not an appropriate candidate for or is unable to tolerate flexible bronchoscopy procedures. * Patient has any disease or condition that interferes with completion of initial or follow-up assessments of the effectiveness endpoints. * Patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures. * Patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study, or is currently participating in another clinical study. * Patient has pulmonary lesions suspected to be cancer from CT images. * Female patient of childbearing potential has a positive result from a pregnancy test.

Design outcomes

Primary

MeasureTime frame
Diagnostic yield of Lung Cancer1 week

Secondary

MeasureTime frame
Number of Participants with Serious Adverse Events1 week

Other

MeasureTime frame
Cost of all examinations to make a diagnosis2 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026